Their post continues: "I’m especially interested in the elementary/middle school teachers’ [opinions] on what behaviors you ...

Children with ADHD hear constant criticism disguised as advice, and most of it makes things worse rather than better. These ...

LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company developing first-in-class, orally delivered immune-tolerance-restoring therapies, announced today that the first patient ...

Cytokinetics announced FDA approval of MYQORZO™ (aficamten) to treat adults with symptomatic obstructive hypertrophic ...

In elderly patients, neurosurgery must ultimately be judged not by what it corrects on imaging, but by what it preserves in ...

The State House Press Association's democratically selected top 10 stories of 2025 are: ...

The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with ...

Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify has developed oral, ...

YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

"How can we do things that are going to help people to thrive in the economic ecosystem where God's placed them?" ...

The mayor has kept his vow to lower crime in New York City, but the city’s economic recovery has stalled and homelessness has ...